Key Highlights

  • HROW down 7% to $35.50 in after-hours trading following Q1 2026 results
  • Q1 2026 Revenue of $44.2 million, impacted by $8 million non-recurring VEVYE gross-to-net adjustment
  • Full-year 2026 guidance reaffirmed at $350–$365 million
  • VEVYE Demand on pace to exceed $100 million in 2026 revenue
  • IHEEZO and TRIESENCE deliver continued strong double-digit unit growth
  • Expanded commercial coverage for VEVYE cited as driver of the one-time adjustment

 

Harrow (Nasdaq: HROW) fell 7 per cent to $35.50 in after-hours trading on Tuesday after the ophthalmic pharmaceutical company reported first-quarter revenue of $44.2 million — a figure that, on the surface, understates the underlying commercial momentum by the amount of a specific and non-recurring accounting adjustment.

The headline revenue number was reduced by an $8 million gross-to-net adjustment related to VEVYE, the company's cyclosporine ophthalmic solution for dry eye disease. Management was explicit that this adjustment was non-recurring and tied to the expansion of commercial coverage for the product — a development that, counterintuitively, triggered a one-time charge in the period in which it occurred. Strip out that adjustment, and the underlying revenue picture is considerably more constructive.

The full-year 2026 guidance reaffirmation of $350 to $365 million is the most important signal in the release. Management's willingness to hold that range despite the Q1 headwind implies confidence that the adjustment was genuinely isolated, and that VEVYE's commercial trajectory — alongside the rest of the portfolio — supports the annual targets. Guidance reaffirmations in the face of apparent quarterly softness are typically read by the market as a form of implicit Earnings upgrade; the after-hours decline suggests investors are applying a more cautious interpretation pending further clarity.

VEVYE itself remains a significant commercial asset. Management indicated that demand is on pace to exceed $100 million in 2026 revenue — a threshold that, if achieved, would represent a material contribution to the company's total revenue base. The expanded commercial coverage that triggered the gross-to-net adjustment is, in the medium term, a positive development: broader payor access typically translates into higher prescription volumes and a larger eligible patient population.

IHEEZO and TRIESENCE, two additional products in Harrow's ophthalmic portfolio, continued to deliver strong double-digit unit growth and Market Share gains in the quarter. IHEEZO, the company's intracameral anaesthetic, has established itself in a niche of the surgical ophthalmology market where clinical Utility and convenience advantages have driven adoption. TRIESENCE, a triamcinolone acetonide suspension for ophthalmic use, has similarly benefited from Supply normalisation and resumed market penetration.

The after-hours decline is characteristic of investor reaction to quarters where the reported number disappoints relative to expectations, even when the underlying Business remains sound and guidance is intact. Harrow's management will have the opportunity to contextualise the VEVYE adjustment and articulate the full-year trajectory in its Earnings Call. The market's ultimate verdict on the stock will likely hinge on whether that explanation is accepted as a credible account of a one-time accounting event rather than a sign of more persistent commercial headwinds.

This article is for informational purposes only and does not constitute Investment advice.